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1. Introduction 
Glioblastoma (GBM, WHO grade IV) is a type of highly malignant brain tumor that 
infiltrates the brain extensively and remains virtually incurable despite being treated with 
gross total resection and post-operative adjuvant radiation and chemotherapy. The vast 
majority of patients with GBM will always develop tumor recurrence. The tumor’s location, 
its unique feature of high motility, and its protection by the blood brain barrier make certain 
therapies that are effective for some other cancers ineffective against brain tumors. Overall, 
the 5-year survival rate is less than 10%, with a final mortality rate of close to 100 percent. 
The molecular mechanisms that underlie persistent tumorigenesis and treatment resistance 
are still poorly understood. A genome-wide expression profile analysis revealed that besides 
those genes associated with cell proliferation, inflammation, angiogenesis, and extracellular 
matrix (ECM) remodeling, a series of genes linked with neuroepithelial stem cells, 
mesenchymal stem cells, skeletal/cartilage development, morphogenesis, and 
organogenesis, were determined to be overexpressed when compared with normal brain 
tissue, implicating that a tissue regeneration/repair-like program is constantly activated in 
GBM tumors. A subset of GBM develops from lower-grade gliomas and can thus be 
clinically classified as ‘‘secondary,’’ whereas some GBM occur with no prior evidence of a 
lower-grade tumor and can be clinically classified as ‘‘primary.’’ Substantial genetic 
differences between these groups of GBM have been identified. Moreover, a molecular 
classification study indicated that both treatment-refractory and untreated primary GBM 
tumors are clustered in a group segregated from treated and untreated secondary GBM 
tumors, and supports the view that GBM subtypes may have derived from a distinct cell-of-
origin, which is resistant to conventional therapy, therefore allowing for re-seeding tumor 
with molecular properties similar to untreated tumors. Thus, post-treatment tumor 
recurrence may mimic the scenario of post-injury tissue repair. Many adult tissues undergo 
renewal after injury, and hence require a new supply of cells originating from specialized 
tissue stem cells with the capability to undergo self-renewal and differentiation to repair 
damaged tissue. Recently, glioblastoma stem cells (GSC) or glioblastoma stem–like cells 
(GSLC), a minor subpopulation within tumor mass, were isolated and characterized as 
tumor-initiating cells and were hypothesized to be responsible for post-treatment recurrence 
because of their enhanced radio-/chemo-resistant phenotype and ability to reconstitute the 
original tumor tissue when grafted into mice. In contrast to the hyperproliferative, 
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 inflammatory, and hyperangiogeneic properties seen in GBM tumors, molecular analysis by 
gene expression profiling revealed that GSC possess neuroectodermal properties and 
express molecular signatures of radial glial cells (RGC) and neural crest cells (NCC), as well 
as portray a migratory, quiescent, and slow-growing phenotype that characterizes tumor 
suppressor properties. Based on the tumor stem cell model and theory, conventional cell 
cycle-targeted radio-chemotherapy, which aims to kill fast-growing tumor cells, would then 
be unable to eliminate post-operative remaining tumorigenic cells that possess quiescent 
stem cell properties. Thus, in order to prevent tumor recurrence, a strategy targeting 
essential gene pathways of GSC must be identified and incorporated into the standard 
treatment regimen. Identifying intrinsic and extrinsic cues, by which GSC maintain 
tumorigenic capacity and antiapoptotic feature to sustain tumorigenesis may highlight 
novel therapeutic strategies to greatly diminish the recurrence rate of GBM and provide 
potentially curative strategies for treating brain cancers. In this chapter, we review 
molecular properties of GBM tumors and GSC. We also summarize molecular signaling 
pathways that have been relatively well-studied in GSC and are essential for maintaining 
GSC stemness, tumorigenic capacity, and radio-chemoresistant phenotype. 
2. Molecular properties of glioblastoma 
2.1 Genetic and clinical pathways to glioblastomas 
GBM remains refractory to conventional therapy. The histopathologic features that 
distinguish it from lower-grade astrocytic tumors are the presence of cellular atypia, mitotic 
figures, necrotic foci with peripheral cellular pseudopalisading, and microvascular 
hyperplasia (1). Two subgroups of GBM have been established based on clinical experience 
and have been affiliated with distinct genetic mechanisms of tumorigenesis. Secondary 
GBM, also known as progressive GBM, develop slowly through progression from low-grade 
glial tumors (WHO grade II) or anaplastic glial tumors (WHO grade III) and frequently 
display p53 mutation (chromosome 17) (~65%) and amplification or overexpression of 
platelet-derived growth factor receptor (PDGFR), but not epidermal growth factor receptor 
(EGFR) (2-3). Additionally, progression to secondary GBM often accompanies an allelic loss 
at chromosome 19q, 17p, and 10q, and a loss of expression of deleted-in-colorectal-
carcinoma gene (DCC) (~50%) but rarely include PTEN mutations (5%) (4-6). The p53 
mutation is usually found in the low-grade lesions, indicating p53 alteration is an early 
event in astrocytoma progression (7). PDGFR amplification or overexpression is also present 
at the early stages suggesting that it may have a role in the progression of these tumors. In 
contrast, loss of heterozygosity for the retinoblastoma-1 (RB1) gene was found in high-grade 
astrocytomas (25%) but not in low-grade astrocytomas, indicating disruption of the RB 
pathway is likely a significant event in the malignant transformation to GBM (8). On the 
other hand, primary GBM, also known as de novo GBM, seem to develop rapidly and 
manifest high-grade lesion from the outset and are genetically characterized by EGFR 
amplification/overexpression (chromosome 7) (~60%), a simultaneous loss of chromosome 
10, but rarely a concurrent p53 mutation. The most common EGFR gene mutation in 
primary GBMs is EGFRvIII, a variant lacking exons 2-7 (corresponding to cDNA nucleotides 
275-1075 encoding amino acids 6–273), which results in a truncated cell surface receptor 
with ligand-independent constitutive tyrosine kinase activity (9-11). This mutation 
presumably occurs through alternative splicing or gene rearrangements (12-13) and leads to 
the loss of binding activation by its normal ligand, EGF and TGF-a (14-15). Mouse double 
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minute 2 (MDM2) amplification that neutralizes p53 activity (16), is observed in more than 
50% of primary GBM, but rarely in secondary GBM. Additionally, CDKN2A (p16INK4a) 
deletion, PTEN mutation, Rb protein alterations and loss of all or a portion of chromosome 
10 are frequently seen in primary GBM (17-18). p16INK4a deletion is infrequent in 
secondary GBMs and its deletion and p53 mutation appear to be two mutually exclusive 
events in GBMs (19). Primary GBMs account for the vast majority of cases (60%) and 
typically occur in the elderly (>50 years old), whereas secondary GBMs, are less common 
(40%) and typically develop in younger patients (<45 y) (4). Primary and secondary GBMs 
are indistinguishable to the neurosurgeon as well as neuropathologist, and the clinical 
management of these two GBM subtypes is identical. To date, temozolomide (TMZ) 
administered daily with radiation therapy (RT) for six weeks, followed by adjuvant TMZ for 
six months, has become standard therapy for patients with newly diagnosed GBM. 
2.2 Genetic characteristics of GBM link to prognosis 
The overall prognosis for patients with GBM is extremely poor. However, a small 
proportion of patients show prolonged survival. A study indicates that different glioma-
associated genomic aberrations may serve as prognostic markers in combination with 
histopathological findings (17). The use of comparative genomic hybridization (CGH)-based 
analysis of 20 primary GBMs suggests that loss of chromosome 10 and gain/amplification in 
chromosome 7 are most frequently observed in primary GBMs and are associated with 
microvascularization and poor prognosis (17). In contrast, the combination of chromosome 
1p and 17p13-p14 and 19q deletions are associated with a longer survival time (5, 17, 20-21). 
The analysis of loss of heterozygosity (LOH) on chromosomes 19q, 1p, and 13q, using 
polymorphic microsatellite markers, however, has indicated that LOH on chromosome 19q 
was frequently found in secondary GBMs (50%) but rarely detected in primary GBMs (20), 
suggesting that tumor suppressor gene(s) located on chromosome 19q are frequently 
involved in the progression from a low-grade astrocytoma to secondary glioblastoma, but 
do not play a major role in the evolution of primary glioblastomas. Clinical trials indicated 
that patients whose tumor had a methylated promoter for the gene encoding O-6-
methylguanine-DNA methyltransferase (MGMT), were more likely to benefit from the 
addition of TMZ to RT (22-23). A recent study further showed that pattern of, and time to, 
recurrence after TMZ concomitant with and adjuvant to radiotherapy are strictly correlated 
with MGMT methylation status (21). Recently, genomewide mutational analysis of GBM 
revealed somatic mutations of cytosolic isocitrate dehydrogenase 1 gene (IDH1), which 
catalyzes the oxidative decarboxylation of isocitrate to ǂ-ketoglutarate, most frequently in 
WHO grade II and III astrocytomas and secondary GBM but rarely in primary GBM (22-23), 
and patient tumors with IDH1 or related mitochondrial IDH2 mutations had a improved 
clinical prognosis than those with wild-type IDH genes (25, 27). It is suggested that IDH 
mutation is a highly prognosis predictor and selective molecular signature of secondary 
GBM (28-29).  
2.3 Molecular classification of glioblastoma subtypes 
Identification of chromosomal abnormalities and cancer-associated genes in solid tumors is 
becoming easier as genome-wide analysis technologies improve and as the genome 
sequence is being completed. These technologies allow for genome-wide data acquisition in 
study of cancer genetics and biology, particularly in analysis of complex expression 
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patterns, in a rapid and efficient fashion. Moreover, since the expression of thousands of 
genes is analyzed simultaneously, we can expect to obtain more comprehensive information 
underlying the interactions of genes related to malignant transformation as well as crucial 
clues about alteration in the relevant genetic and biological networks (30). Since the genetic 
basis of human cancer is combinatorial, this approach becomes especially important when 
combined with computational technology (31). Likewise, genomic mutation (e.g. deletions, 
inversions, chromosome re-arrangement, amplification, promoter mutation) and 
posttranslational modifications of proteins are the key factors that induce and maintain the 
malignant transformation of cancer. The success of using gene expression patterns to study 
cancer will depend largely on how much they reflect genomic changes. If a significant 
portion of the effects of genomic abnormalities can be reflected at the RNA level, the gene 
expression patterns will be highly informative and can be analyzed to explain the molecular 
mechanisms underlying the pathological development and behavior of cancers (32). GBM 
tumor heterogeneity is likely to play a significant role in explaining the unsuccessful 
treatment modalities. Therefore, molecular classification with large–scale expression assays 
will be more prognostically and therapeutically significant (33-34) since comprehensive and 
unbiased information can be obtained and would allow for the development therapies 
specifically tailored to each subtype. Multiple studies also indicate that gene expression-
based classification of malignant gliomas correlates better with survival than histological 
classification (35). Successful integration of molecular/genetic data into tumor status must 
be descriptive and partially explain known tumor behavior, pathology, and resistance to 
therapy, as well as provide an insight to how the deregulation of multigene networks leads 
to tumor development, progression and treatment resistance (32, 36-37).  
2.3.1 Glioblastoma subtypes express distinct transcription profiles 
To identify whether molecular profiling can distinguish GBM subtypes, we and others have 
performed genome-wide microarray expression profiling and identified molecular subtypes 
that express distinct genes associated with tumor progression and predict clinical outcome 
better than histological class (35, 37-38). In general, using molecular profiling, GBM can be 
classified into three major subtypes include proliferative, mesenchymal and neuronal 
phenotypes (38-39), and the poor prognosis tumor subtypes are distinguished by the 
molecular markers of proliferation or mesenchymal/ECM/angiogenesis, which the majority 
is associated with losses on chromosome 10 that span 10q23.3 and gain on chromosome 7. In 
particular, most cases of mesechymal GBM had relative losses at all loci on chromosome 10 
and gains of all loci on chromosome 7, whereas proliferative tumors had more 
heterogeneous pattern of losses chromosome 10 (38). However, upon recurrence, GBM 
tumors tend to shift toward mesenchymal phenotype (38, 40). In order to elucidate whether 
primary and secondary GBM subgroups use distinct molecular pathways as well as identify 
gain-of-function genes that are associated with acquisition of malignant features of GBM 
subtypes, we have performed a large-scale DNA microarray analysis to compare the mean 
level of normalized transcript levels in each of the two clinically defined GBM groups versus 
the grade II and III astrocytomas. We have identified shared and non-shared GBM-
associated gene (GAGs) over-expressed by respective subtype (40). As anticipated, shared 
GAGs reflect common characteristics of hyperproliferation, hypervascularity, and apoptotic 
resistance in both GBM subgroups, whereas GAGs distinct to primary or secondary tumors 
provided information on the heterogeneous properties and apparently distinct oncogenic 
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mechanisms of these tumors. Secondary GBM-associated GAGs were mostly related to the 
mitotic cell cycle (Figure 1A), which corresponds to the fact that secondary GBM have high 
frequencies of TP53 and Rb mutations (2-3). Moreover, secondary GAGs reflect the causes 
and effects of such genotypic and phenotypic changes. Therefore, the molecular properties 
of secondary GBM support the notion that mutation or dysfunction of cell cycle regulators 
would be the major mechanism responsible for the development of malignant phenotype in 
secondary GBM. In contrast, primary GAGs highlight genes typical of a 
stromal/inflammatory response and are strongly associated with invasive phenotype, 
suggesting the importance of extracellular signaling (Figure 1B). The molecular properties 
of primary GBM thus support the view that the interplay between GBM derived 
bone/cartilage-associated factors and tumor-associated stromal cells play a key role in the 
malignant transformation of primary GBMs. To rule out the possibility that the distinct 
GBM progression-associated genes identified between the two subgroups are due to 
selection pressure (e.g. radiation or chemotherapy), we further conducted clustering-based 
analysis of a set of primary GBM (n=13) that are recurrent and had prior treatment and 
secondary GBM (n=12) samples that had been treated during grade step prior to tumor 
sampling, using these identified GAGs. The results indicate that both tumor subtypes, 
regardless of prior treatment, cluster within their clinical grouping based on gene expression 
of the selected GAGs (Figure 2). Of note, 85% of recurrent primary GBM are clustered to 
mesenchymal GBM and 83% of secondary GBM are clustered into cell-cycle GBM, 
indicating that prior treatment is not disrupting this identified gene expression signature of 
primary and secondary GBM nor driving the selection of the genes. These data therefore 
support the notion that diverse mechanisms and properties underlying distinct 
transformation events or perhaps distinct cells of origin of GBM subtypes. 
2.3.2 Primary glioblastoma express mesechymal stem cell properties 
The most striking observation in the molecular properties of primary GBM among all is 
the series of genes highly expressed in mesenchymal tissues, but not in neural or glial 
cells, were identified. These overexpressed genes are related to osteogenesis and 
chondrogenesis (e.g. cartilage glycoprotein-39/YKL-40, chitinase 3-like 2, glycoprotein 
nmb, lysyl oxidase, lung type-I cell membrane-associated glycoprotein, collagen type V, 
VI, biglycan, mesenchyme homeobox 2, and fatty acid–binding protein). These molecular 
properties characterized a mesenchymal phenotype of these glial tumors. To access gene 
pathways that are potentially associated with tumor development of primary GBM, a 
comparative analysis of primary GBM (n = 46) relative to normal brain tissue (n = 10) was 
performed. As anticipated, genes that were previously identified as primary GBM 
progression-associated genes reappeared in this gene list, which reflected the status of 
inflammation, coagulation, immune/complement responses, angiogenesis, and ECM 
remodeling (40, Figure 1B). Strikingly, a new series of genes linked with neural stem cells 
(NSC), mesenchymal stem cells (MSC), skeletal/cartilage development, morphogenesis, 
organogenesis, and embryonic neuroepithelial stem cells was determined. It thus 
implicates that a tissue regeneration/repair program is constantly activated in GBMs 
(Figure 3). Furthermore, a subset of primary GBM tumor-derived tumor lines expresses 
cellular markers that are associated with MSC (CD90, CD105, CD29, and CD44) and that 
GBM cell cultures can be induced to differentiate into multiple mesenchymal lineage-like 
cell types, including adipocytes, chondrocytes, and osteocytes (41). These findings suggest  
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Fig. 1. Glioblastoma-associated genes (GAGs) overexpressed in GBM subtypes relative to 
lower grade gliomas. All plots show normalized gene expression values converted into a 
heat map. The log2 of the fold difference is indicated by the heat map scale at the bottom of 
the Figure. Each column is an individual tissue or tumor sample organized into histologic 
groups defined at the top of the figure. Each row is a single probe set measurement of 
transcript abundance for an individual gene. All genes were filtered to select transcripts 
with 2.5-fold or higher expression in the respective GBM group relative lower grade 
astrocytomas (P value < 0.05, t-test). A. GAGs overexpressed uniquely in secondary 
glioblastomas: 21 secondary GAGs were defined as being uniquely detected with a >2.5-fold 
overexpression in the secondary GBM group compared with the lower-grade astrocytomas 
and not overexpressed within the primary glioblastoma group. B. GAGs overexpressed 
uniquely in primary GBM: 58 primary GAGs were defined as overexpressed 2.5-fold 
relative to lower-grade astrocytomas and not detected in the secondary glioblastomas 
comparison using the same criteria. Functional categories of gene clusters in gene-ontology 
(GO) terms were shown and were analyzed using a GO annotation–based gene function 
enrichment analysis (d-chip software). Gene description listed in Figure 2. 
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Fig. 2. Unsupervised sample clustering of primary and secondary GBM that are recurrent 
and had treatment using 21 secondary GAGs (Figure 1A) and 58 primary GAGs (Figure 1B). 
Distinct GAGs segregated GBM subtypes, suggesting they may be repopulated by GBM 
stem cells with distinct molecular properties. PG= progressive/secondary GBM. DG= de 
novo/primary GBM. 
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Fig. 3. A comparative analysis of gene expression profiles in primary GBM (n = 46) and 
normal brain tissue (n = 10). Analysis was based on a cutoff of a 2.5-fold increase in relative 
expression (P < 0.05). Top 100 primary GBM-associated genes expressed at higher levels 
compared with normal brain tissue were extracted. Functional categories of gene clusters in 
gene-ontology (GO) terms were shown. 
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that either a subset of primary glioblastomas derives from transformed stem cells containing 
MSC-like properties and retains partial phenotypic aspects of a MSC nature in tumors, or 
that GBMs activate a series of genes resulting in mesenchymal properties of the cancer cells 
to effect sustained tumor growth and malignant progression. Since primary GBM express 
both NSC (e.g. nestin, SOX2) and MSC makers, it is hypothesized that a subset of GBM 
tumors may be derived from neural crest-stem-like cells (41). The lack of MSC-like 
properties in secondary GBM may suggest that they originate from a different cell type of 
cellular origin. Further characterization of stem-like cells in GBM tumors would help to 
identify new targets and subsequently develop new therapeutic strategies to delay tumor 
progression and prevent tumor regeneration. 
3. Glioblastoma stem cells 
3.1 Glioblastoma contain tumorigenic stem -like cells 
Tumorigenic, stem-like GBM cells, or so-called glioblastoma stem cells (GSC) have been 
recently isolated and characterized as GBM tumor-initiating cells by multiple groups (42-
46). Although CD133/prominin, a normal NSC marker, is not an obligatory marker for 
GSC (46-47), CD133 was first applied as a surface marker for isolation and enrichment of 
GSC (42, 44-46, 48-49). Other surface markers are also reported to be used for GSC 
isolation and enrichment, including Musashi homolog 1 (MSI1) (50), and A2B5 (51). 
Through studies in both in-vitro and in-vivo GSC functional models, several essential 
genes and signaling pathways for maintaining tumorigenic potential have been 
implicated. At the functional level, GSC behave in ways similar to tissue stem cells, are 
capable of self-renewal and differentiation, and reconstitute the tumor tissue when 
grafted into mice. GSC possess a multi-lineage differentiation capacity also support for 
the hypothesis that cancer hierarchy is a result of developmental diversity among cancer 
cells in different states of differentiation (52-54). However, it is plausible that multiple 
genetic and/or epigenetic instabilities that take place within tumor stem cells might 
prevent progeny from undergoing non-proliferative terminal differentiation, leading to 
uncontrolled tumor growth (55-57). Tumors initiated in mouse brain by injection of 
patient-derived GSC often recapitulate the histopathological features of the patient 
tumors from which the cells were derived, indicating the ability to self-renew and 
reproduce the cellular heterogeneity found in human GBM tumors (44-45, 47-48). 
Uniquely, we found GSC isolated from treatment-refractory recurrent GBM tumors can 
spontaneously migrate radially outward from tumor spheres that they initiated and 
populated in cultures followed by spread out over the surface of the culture dish and 
form the secondary tumor spheres without additional factors added into the culture to 
influence the behavior of cells (Figure 4). This in-vitro observation suggests that the 
migratory nature of GSC is likely to be an intrinsic property that reflects inherently 
migratory properties of the GBM tumor of origin. Likewise, an intracranial injection of 
these GSC leads to the development of YKL-40+ infiltrative tumors that display 
hypervascularity and pseudopalisading necrosis-like features in mouse brain (Figure 4). 
Thus, it is possible that tumor recurrence in the secondary site may be due to tumor stem 
cells escaping from primary treatment, migrating out of core mass, infiltrating adjacent 
brain tissue, and continuing seeding a new tumor. Importantly, GSC were shown to resist 
the effects of ionizing radiation and chemotherapy (58-59) with a marked increase in 
activation of several checkpoint proteins in response to DNA damage, pointing to they 
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may be responsible for the post-treatment tumor recurrence. Thus, identification of genes 
and pathways confer the migratory ability, anti-apoptotic features, and tumorigenic 
capacity of GSC would be essential for better understanding GSC and identifying 
potential targets in order to eradicate and prevent them from regenerating a new tumor. 
 
 
Fig. 4. Patient-derived glioblastoma stem cells (GSC) are highly motile cells and are capable 
of populating tumor spheres in cultures and initiating an infiltrating tumor in mouse brain. 
GSC isolated from treated and recurred tumor possess the ability to clonally self-renew, 
form primary tumor sphere (a), migrate outward (b), form secondary tumor spheres in 
secondary sites (c), and display pseudopalisading necrosis–like morphology (d). Immuno-
fluorescent staining showed GSC spheres co-express CD133 and SOX2 (e) and can be 
propagated in cultures for indefinite passages. Brain tissues from mice injected with GSC 
display invasive growth of gliomas with diffuse infiltration into the surrounding tissue and 
exhibit hypercellular zones surrounding necrotic foci (f-h). Immunohistochemistry staining 
showed positivity in CD31/platelet endothelial cell adhesion molecule, YKL-40, and nestin, 
indicating an angiogenic progression of gliomas (i-l). 
3.2 Molecular properties of tumorigeneic glioblastoma stem cells 
Isolation and characterization of tumorigenic GSC derived from treatment-refractory GBM 
tumor may have a clinical implication of identifying innovative molecular targets for the 
development of a more effective treatment protocol. Particularly, elucidation of essential gene 
pathways of GSC that confer sustained self-renewal, cell migration and cell survival will be 
vital important for targeting and preventing of GSC mediated-tumor recurrence. Gene 
expression profile analysis revealed that purified, tumorigenic CD133+ GSC derived from 
treatment-refractory recurrent brain tumors possess neuroectodermal properties and portray 
astrogliogenic and chondrogenic potential. Moreover, CD133+GSC express molecular 
signatures for multiple adult stem cells, including RGC (e.g. fatty acid binding protein 7, 
secreted protein acidic and rich in cysteine-like 1), NCC (e.g. endothelial 3, Distal-less homeo 
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box 5/6, v-myc myelocytomatosis viral-related oncogene), NSC (e.g. SOX2, nestin), MSC (e.g. 
CD44, CD105), and stem cells in the small intestine and colon (e.g. Leucine-rich repeat-
containing G protein-coupled receptor 5). More strikingly, in contrast to hyperproliferative 
and hyperangiogenic phenotype of GBM tumors, purified CD133+ GSC, not CD133+ 
glioblastoma spheres (containing mostly CD133- progeny), express a tumor-suppressor 
phenotype, which is characterized by the expression of a series of genes associated with an 
anti-growing, anti-inflammatory, anti-angiogenic, anti-developmental, and migrating 
phenotype (42). This observation implicate that these GSC may be clinically 
indolent/quiescent prior to undergoing proliferative cell division, which would produce 
proliferative and angiogenic GBM effector progeny. Thus, it is possible that some migratory, 
tumorigenic GBM-stem like clones may use properties of stem cell quiescence to evade first-
line treatment and regrow a new tumor at a secondary site after treatment. The molecular 
properties of GSC also support the view that genes guarding the pools and tumorigenic 
potential of GSC may not be in the subgroup of genes directly controlling cell proliferation, but 
in the subgroup regulating cellular quiescence, development, differentiation, and survival. 
Analysis of the expression of the CD133 in gliomas found that both the proportion of CD133+ 
cells and their topological organization in clusters were significant prognostic factors for 
adverse progression-free survival and overall survival (60). Computational comparisons with 
a collection of published gene expression profiles further reveal that the CD133 gene signature 
transcriptionally resembles human embryonic stem cells (ES) and GSC, and this signature 
successfully distinguishes glioblastoma from lower-grade gliomas, and identify an aggressive 
glioblastoma subtype with excess mutation (61). To date, most anti-cancer therapies aim to 
eliminate rapidly proliferating tumor cells; thus, the discovery of treatment-resistant, quiescent 
GSC (42, 58-59, 62) possessing the enhanced ability to repopulate tumors provides an excellent 
model to explain our inability to eradicate brain tumors (Figure 5). The identification of genes 
and pathways and performing pre-clinical validation of gene function in animal experiments 
may facilitate the discovery and development of innovative treatment protocols for the 
prevention of post-treatment tumor recurrence through the targeting tumorigenic stem-like 
GBM cells, which is not targeted in any current anti-cancer treatment.  
4. Essential gene pathways for GSC 
4.1 In-vitro cultivation of tumorigenic GSC 
It is plausible that the quiescent, migratory, and tumorigenic properties render GSC an 
excellent candidate for being responsible for post-treatment tumor recurrence. Based on the in 
vitro and in vivo characterization of GSC, the GSC population is being considered a dynamic 
fraction of cells highly sensitive to microenvironmental changes or stimulation (e.g. self-
renewal and differentiation). Therefore, identifying both intrinsic and extrinsic signaling 
pathways by which GSC maintain the tumorigenic capacity to support continuous tumor 
growth will facilitate the development of novel therapeutic strategies to diminish the 
recurrence rate of glioblastoma tumors. Current experimental models for the study of GSC in 
the laboratory have been relatively standardized. In laboratory, GSC are maintained in serum-
free media supplemented with epidermal growth factor (EGF) and fibroblast growth factor 
(FGF) and are able to propagated as a non-adherent or semi-adherent sphere cultures for 
indefinite passages. More importantly, GSC are capable of clonal self-renewal and proliferative 
differentiation, thereby allowing populate single cell-derived tumor spheres in cultures. 
Genome-wide expression microarray analysis of GSC have identified a series of 
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Fig. 5. A theoretical model of glioblastoma stem cells (GSC) contribute to both tumorigenesis 
and treatment resistance. GSC use both symmetric and asymmetric division to sustain self-
renewal and proliferative differentiation to initiate and maintain a tumor. GSC contain both 
quiescent and active cell types; the quiescent GSC are slow-cycling, radio-chemoresistant, 
and capable of unlimited self-renewal, whereas the activated GSC can undergo proliferative 
differentiaion and initiating a tumor. Progeny of GSC populate a tumor containing a 
heterogeneous population in different states of differentiation, and are fast-growing, 
angiogenic, and radio-chemosensitive. Quiescent GSC can escape from radio-chemotherapy 
and continually replenish tumor cells, leading to sustained tumorigenesis. 
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molecular markers associated with adult stem cells (42) and a recent study further showed 
that GSC express EC markers which can distinguish GSC from NSC (63). GSC possess 
tumorigenic potential, and by contrast to regular glioblastoma cell lines cultured in 
serum-containing media, injection of lower number of GSC into mice with severe 
combined immune deficiency (SCID) is able to initiate and reconstitute GBM tumors in 
mouse brains, which recapitulate the histopathological features of the patient tumor from 
which the GSC were derived (42-47). Thus, by using these well-documented in-vitro and 
in-vivo functional assays of GSC, which can be visualized, assayed, and quantified, 
investigators have discovered and established several essential gene pathways by which 
properties and function of GSC can be maintained; in particular, studies using small 
interfering RNA (siRNA)-mediated loss-of-function phenotype, a particular gene pathway 
that is involved in maintaining GSC can be identified and verified. Thus, by both in-vitro 
and in-vivo GSC functional models, several essential genes and signaling pathways for 
maintaining GSC stemness, tumorigenic capacity, and anti-apoptotic features have been 
implicated (64, Review).  
4.2 Notch signaling pathway  
Several Notch effector genes, including inhibitor of differentiation 4 (ID4) (65), hairy and 
enhancer of split 1 (HES1) (66), hairy/enhancer-of-split related with YRPW motif 1 
(HEY1) (67) and fatty acid binding protein 7 (FABP7) (68), have been detected in GSC by 
expression microarray analysis, thereby reflecting the prolonged Notch activation (42). 
Notch signaling controls numerous cell fate specification events, and it has been 
implicated in the maintenance of cellular quiescence in many adult stem cell pools by 
retaining self-renewal potential, suppressing cell differentiation, and protecting them 
from exhaustion of their proliferative capacity (66, 69-70). The Notch signaling network is 
composed of a family of four Notch receptors (Notch1, Notch2, Notch3, Notch4) and five 
ligands from the members of the Delta-like (DLL1, DLL3, DLL4) and the Jagged (JAG1, 
JAG2) families. The signaling permits the gamma secretase–mediated proteolytic release 
of the Notch intracellular domain (NICD), which translocates into the nucleus and 
transactivates target genes. Notch signaling regulates NSC differentiation; indication of 
Notch signaling drives NSC into quiescence, whereas blocking Notch signaling stimulates 
NSC undergo neurogenesis (69, 71). Moreover, Notch signaling is required to convert the 
hypoxic stimulus into epithelial–mesenchymal transition (EMT), increased motility, and 
invasiveness (72). Thus, expression of Notch effector genes in GSC implies abrogation of 
neurogenesis, promoting a migratory phenotype and enhancing glial-fate specification. 
Importantly, increased expression of FABP7 was found to be associated with regions of 
GBM tumor infiltration (73), suggesting that Notch activation in GSC may not only 
maintain the stemness of GSC, but also promote a infiltrating characteristics of brain 
tumor. Treatment of GBM sphere cultures with gamma-secretase inhibitors (GSIs) can 
deplete GSC, downregulate stem cell markers (CD133, nestin, BMI1, Olig2), and inhibit 
self-renewal of GSC in cultures and growth of xenografts (74). The depletion of 
tumorigenic GSC by Notch signaling blockade was found to occur via reduced cell 
proliferation and increased cell apoptosis due to decreased levels of phosphorylated AKT 
and STAT3 (75). In addition, it has be shown that tumor endothelial cells support GSC 
maintenance, which is in part via Notch signaling (76) and suggested that inhibition of 
Notch signaling can target GSC via an endothelial cell intermediate.  
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4.3 Hypoxia and hypoxia-inducible factors 
It has been shown that hypoxia-inducible factors (HIFs) regulate tumorigenic capacity of 
GSC (77-78). When glioblastoma sphere cultures are grown in 1% oxygen, hypoxic 
response genes, including HIF-1, HIF-2, lysyl oxidase, and vascular endothelial growth 
factor (VEGF), are greatly induced, in addidton, both the stem-like side population and 
CD133+ cells were increased (79). Moreover, GSC respond to hypoxia by enhancing their 
self-renewal activity and anti-differentiated status (80). Loss of HIF-2ǂ in GSC leads to a 
significant decrease in both GSC proliferation and self-renewal in cultures, and 
attenuation of tumorigenic capacity in animals (80). Hypoxia requires Notch signaling 
for maintaining cells in an undifferentiated state, which occurs by recruiting HIF-1ǂ to 
the promoters of Notch-responsive target genes (81). The maintenance of GSC by a 
hypoxic microenvironment via enhancing the activity of other stem cell factors such as 
Oct4, c-Myc, and Nanog, also partially promotes and stabilizes the stem cell phenotype 
(77, 82). Thus, HIFs might potentially represent a promising target for depleting GSC 
populations.  
4.4 GLI – Nanog axis 
Nanog and Hedgehog (HH) are two essential regulators of stemness in ES. HH proteins act 
through the Patched (Ptc) and Smoothened (Smo) and ultimately activates the GLI family of 
transcription factors. HH-GLI signaling modulates neural progenitor proliferation and 
survival in the developing neural tube, and controls stem cell behavior in the postnatal and 
adult brain (83-85). Nanog, a pluripotency homeobox gene, is regulated by HH-GLI 
signaling via binding of HH effectors, Gli1 and Gli2, to the Nanog promoter, thus activating 
Nanog expression (86). A study shows that HH-GLI signaling regulates glioma growth, GSC 
self-renewal, and tumorigenic capacity, and the blockade of HH-GLI signaling by treatment 
with cyclopamine depletes GSC (87). Nanog was recently reported to be a novel HH-GLI 
mediator for expanding CD133+ GSC and promoting glioblastoma growth (88). More 
importantly, it was found that loss of tumor suppressor p53 activates HH-GLI signaling, 
thereby contributing to Nanog upregulation and leading to the promoting of GSC stemness. 
In contrast, the presence of p53 can negatively regulate the activity and level of GLI1, thus 
downregulating Nanog expression (86, 88-89). Therefore, the inversely reciprocal levels of 
GLI1 and p53 are consistently maintained in GSC (88). Concurrently, GLI1 upregulates 
Notch and downregulates bone morphogenetic protein (BMP) signaling, a pro-
differentiative action on stem cells (89), implying an essential role of a functional GLI1-
NANOG-p53-Notch network in maintaining stemness and tumorigenic capacity of GSC. 
Thus, GLI–Nanog axis provides a potential treatment target for the prevention of GSC- 
mediated tumor recurrence. 
4.5 Transforming growth factor beta (TGFβ) signaling  
The TGF-ǃ signaling pathway plays an essential role in the regulation of embryonic 
development, cell proliferation, motility and apoptosis, ECM production and modulation of 
immune function (90). The TGF-ǃ superfamily comprises both growth and differentiation 
factors including TGF-ǃs, activins, inhibins, and bone morphogenetic proteins (BMPs). 
TGFǃ signaling by binding to type I and type II receptors on the cell surface. The type II 
receptor phosphorylates the type I receptor, which propagates the signal by 
phosphorylating receptor-activated SMAD (R-SMAD) proteins (91) that transduce TGF-ǃ 
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family signals into a transcriptionally regulated developmental program. A recent study 
showed that the TGFb/activin signaling pathway is essential for the maintenance of ES cells, 
which is via binding of SMAD2/3 to the NANOG proximal promoter in human ES (92). 
Alternatively, TGFǃ signaling can act through Smad-independent pathways, which activate 
Ras/extracellular signal-regulated kinase (ERK), TGFǃ-activated kinase-1/p38 mitogen-
activated protein kinase (MAPK)/c-Jun NH2-terminal kinase (TAK1/P38/JNK), 
phosphatidylinositol 3-kinase(PI3K)/AKT, and signal transducers and activators of 
transcription 3 (STAT3) (93-94). A study showed that TGFǃ signaling promotes the self-
renewal and tumorigenic capacity of GSC by Smad–dependent induction of leukemia 
inhibitory factor (LIF) (95). Treatment of GSC with recombinant LIF induced a rapid 
phosphorylation of STAT3. Thus, TGFǃ signaling promotes GSC self-renewal through the 
activation of JAK-STAT pathway by the induction of LIF secretion (95). Mice receiving GSC 
pre-treated with a TGFǃ receptor inhibitor and a JAK inhibitor significantly increased the 
survival rate compared to the group receiving non-treated GSC, indicating the TGFǃ and 
JAK-STAT signaling pathways play an essential role for maintaining tumorigenic potential 
of GSC (95).  
A direct mechanistic link of STAT3 activation to GSC growth and self-renewal was further 
evidenced by two separated studies, demonstrating that knockdown of STAT3 signaling by 
a short hairpin RNA (shRNA) or inhibitors of STAT3-DNA binding, leads to loss of capacity 
for tumor sphere formation, induction of cell apoptosis, and a decrease in tumor-initiating 
capacity in animals (96-97). Therefore, these data suggest that the STAT3 signaling pathway 
may be a potential target for GSC-directed brain tumor therapy. Since STAT3 signaling is a 
downstream effector of interleukin-6 (IL-6), blockade of IL-6R alpha or IL-6 expression with 
shRNAs also suppresses tumor sphere formation capacity and increases survival of mice 
bearing intracranial glioblastoma xenografts (98). Another related study showed that 
autocrine TGF-beta signaling maintains stemness of GSC by induction of Sry-related HMG-
box 2 (SOX2), one of the key transcription factors required in induced pluripotent stem cells, 
and this induction was mediated by Sox4, a direct TGF-beta target gene (99). Thus, 
treatment with inhibitors of TGF-beta signaling drastically deplete GSC by promoting their 
differentiation, and leads to less lethal potency in intracranial transplantation assay. SOX2 
silencing or induction of GSC differentiation by treatment with bone morphogenetic protein 
4 led to the loss of self-renewal capacity and tumorigenicity of GSC (62, 100-101), indicating 
the maintenance of the undifferentiated phenotype is one of the key criteria for retaining 
tumorigenic capacity of GSC.  
4.6 Epidermal growth factor receptor (EGFR) and down-stream AKT, MEK (mitogen-
activated protein kinase/ERK kinase), and ERK 1/2 signaling 
EGFR is commonly amplified and/or mutated in high-grade gliomas. A study showed 
that EGFR signaling pathway is involved in the maintenance of GSC and is required for 
gliomagenesis (102). Treatment of GSC with tyrosine kinase inhibitors of EGFR signaling 
suppresses GSC self-renewal and induces cell apoptosis through the inhibition of 
phosphorylation of EGFR, AKT kinase, and ERK 1/2 (103-104). Likewise, GSC display 
preferential sensitivity to Akt inhibition relative to matched non-GSC cells and inhibition 
of Akt activity in GSC increased the survival of animal bearing human glioma xenografts 
(105). Similar results are also demonstrated by a targeted inactivation of MEK/ERK 
signaling, which led to the reduction of sphere-forming capacity of GSC accompanied by 
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their differentiation into neuronal and glial lineages (106). Moreover, combinational 
blockade of both MEK/ERK and PI3K/mTOR pathways suppressed the tumorigenic 
capacity of GSC more effectively than blockade of either alone (107). These results 
therefore indicate that the EGF/EGFR signaling and its downstream effector activation 
are essential for maintaining GSC, suggesting a potential molecular pathway target for 
depletion of GSC.  
4.7 c-Myc 
c-Myc belongs to a family of transcription factors containing basic, helix-loop-helix, and 
leucine zipper domains and it is an essential factor for normal embryonic development 
(108). c-Myc is an oncogenic transcription factor commonly overexpressed in a variety of 
human cancers. In contrast, c-Myc gene inactivation triggers telomere-independent 
senescence mediated by the cyclin-dependent kinase inhibitor p16INK4a, which is regulated 
by the polycomb group repressor Bmi-1, a direct transcriptional target of c-Myc (109). High-
level of c-Myc expression was found in GSC relative to non-stem glioma cells, and 
knockdown of c-Myc in GSC induces cell apoptosis and leads to the loss of tumorigenic 
capacity (110). A recent study further showed that HIF-2ǂ promotes GSC self-renewal and 
stemness properties via enhancing the expression of c-Myc (82), and inactivation of PTEN 
and p53 can also lead to the increased expression of c-Myc and promotion of stemness, self-
renewal and the tumorigenic capacity of GSC (111). These data suggest that the c-Myc 
signaling pathway is required for maintaining the self-renewal capability and tumorigenic 
potential of GSC, and therefore may serve as a potential signaling pathway target for a GSC 
–directed brain cancer therapy.  
4.8 L1 cell adhesion molecule (L1CAM), Olig2, Bmi-1, integrin α6, and A20 
L1CAM is a cell adhesion molecule plays an important role in nervous system 
development, including neuronal migration and differentiation (112). L1CAM expression 
was found to be preferentially higher in GSC compared to normal neural progenitors, and 
knockdown of L1CAM expression via shRNA interference can lead to the loss of sphere-
forming capacity, induced cell apoptosis, and suppressed tumor growth (113). The 
induction of GSC apoptosis by decreasing the expression of L1CAM is suggested due to 
the decreased expression of the basic helix-loop-helix transcription factor Olig2 and the 
increased expression of the p21WAF1/CIP1 tumor suppressor (113). Correspondingly, it 
has been shown that an Olig2-regulated lineage-restricted pathway is critical for 
proliferation and maintenance of tumorigenic GSC through the suppression of 
p21WAF1/CIP1 (114).  
Bmi1 plays an essential part in the self-renewal of hematopoietic stem cells (HSC) and NSC 
(115-117). Bmi1 is part of the Polycomb group gene family and a member of polycomb-
repressing complex 1 (PRC1), which is required to maintain the transcriptionally repressive 
state of many genes by chromatin remodeling and histone modification (118-119). It has 
been shown that Bmi-1 is highly expressed in CD133+ GSC and Bmi-1 knockdown resulted 
in inhibition of self-renewal capacity and induction of both cell apoptosis and cell 
differentiation, as well as loss of tumorigenic capacity (120). Similarly, disruption of EZH2, 
the main component of PRC2, robustly impairs self-renewal and tumorigenic capacity of 
GSC (121). This data thus suggest that PcG proteins are required for maintaining stemness, 
survival, and tumorigenic capacity of GSC.  
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Integrins are one of the major families of cell adhesion receptors that cells use to both bind 
to and respond to the ECM (122). Specifically, integrin ǂ6 subunit is critical for the early 
development of the nervous system and has been shown to play a role in neuronal 
migration, neurite outgrowth, and axon guidance during olfactory development (123). A 
recent study showed that GSC highly express integrin ǂ6 and their interaction with laminin 
on endothelial cells directly regulates the tumorigenic capacity of GSC (124). Targeting 
integrin ǂ6 in GSCs inhibits self-renewal, proliferation, and tumor formation capacity (124), 
indicating integrin ǂ6 is an essential factor for maintaining GSC and can be potentially used 
as a cellular target for depletion of GSCs.  
Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) or A20, a zinc finger protein, is 
an NF-κB-inducible gene. A20 can protect the cells from TNF-induced apoptosis by 
disrupting the recruitment of the death domain signaling molecules TRADD and RIP to 
the receptor signaling complex (125). A novel anti-apoptotic mechanism of A20 was 
recently reported and showed that A20 blocks TNF-induced apoptosis through 
suppression of c-jun N-terminal kinase (JNK) by targeting apoptosis signal-regulating 
kinase1 (ASK1) (126). A20 was overexpressed in clinical glioma tissue samples and 
correlates to clinical staging (127). A recent study showed that GSC overexpress A20, 
relative to non-stem glioma cells, and this protects GSC from cell death (128). Inhibiting 
A20 expression by shRNA (shRNA) decreased GSC growth and survival through 
mechanisms associated with decreased cell-cycle progression and decreased 
phosphorylation of NF-kappaB p65(RelA). By contrast, elevated levels of A20 in GSCs 
contributed to apoptotic resistance and were less susceptible to TNFalpha-induced cell 
death than matched non-stem glioma cells. A20 knockdown reduced the self-renewal 
ability of these cells and decreased tumorigenic potential of GSCs, thereby resulting in 
increased survival of mice bearing human glioma xenografts. Thus, A20 contributes to 
glioma maintenance likely through anti-apoptotic effects on GSC. 
5. Gene pathways underlying the radio-chemoresistant phenotype of GSC 
Concurrent TMZ and RT followed by adjuvant TMZ is standard for patients with newly 
diagnosed glioblastoma based on a large randomized phase III trial that showed survival 
benefit (129-130). Studies further showed that patients whose tumor had a methylated 
promoter for the gene encoding O6-methylguanine-DNA methyltransferase (MGMT), a 
DNA repair protein, were more likely to benefit from the addition of TMZ (22, 130). 
Although the survival advantage of combined treatment lasts up to 5 years of follow-up, 
most patients successfully treated with combined therapy eventually had tumor 
recurrence and died (130). A significant increase in MGMT expression was found in first 
recurrence after treatment with RT plus TMZ, indicating either selection of MGMT-
expressing cells or induction of the MGMT gene by TMZ (131). Molecular analysis of 
glioblastoma tumors resistance to the concomitant radio-chemotherapy with TMZ had 
identified a self-renewal signature dominated by homeobox (HOX) genes, which are 
comprised of CD133 (132). Of note, tumors with the enhanced expression of HOX genes, 
high EGFR expression, plus unmethylated MGMT were associated with short survival 
(132), implicating the association of stem-cell phenotype and radiochemoresistance. It is 
plausible that the quiescent stem cell nature adopted by GSC may explain the 
considerable resistance to chemotherapeutic agents (133-136). Moreover, quiescent cells 
show greater repair capacities than proliferative cells (58, 135), suggesting that slow-
www.intechopen.com
  
Management of CNS Tumors 
 
44
cycling GSC may play a key role in the acquired or constitutive resistance to radio-
chemotherapy (137).  
5.1 Activation of checkpoint proteins 
A study indicated a potential role of DNA damage checkpoint protein, Chk1 and Chk2 
kinases in the radioresistant phenotype of CSC (58). Particularly, CD133+ GSC isolated from 
glioblastoma tumors preferentially activated Chk1/2 kinases, and repaired radiation-
induced DNA damage more effectively than CD133- non-GSC cells (58), indicting stem-like 
glioblastoma cell population within tumor mass are likely responsible for the treatment 
resistance. This notion was further supported by the demonstrating that the radioresistant 
phenotype of GSC can be reversed by the treatment with a specific inhibitor of the Chk1 and 
Chk2 checkpoint kinases (58).  
5.2 Evasion of cell-death pathway 
Evidently, GSC exhibit enhanced chemoresistance to anticancer drugs (59, 138-139). The 
expression of ATP-binding cassette transporter ABCG2 in a tumorigenic stem-like side 
population (SP) distinguish them from the non-stem-like cells (138), suggesting a potential 
mechanism underlying chemoresistance in CSCs. Several anti-apoptotic genes (e.g. BCL-2, 
BCL2L1a, and MCL1) were also found to be at higher expression levels in TMZ resistant-
GSC clones than those in differentiated cell lines (140). Likewise, CD133+ GSC were 
characterized by the enhanced expression of multidrug resistance 1 (MDR1) compared to 
CD133- non-stem cells (139). Moreover, the radio-resistance of GSC could be alleviated by 
treatment with an XIAP inhibitor (141). Thus, the radio-chemoresistance of GSC may be 
linked to the activation of the DNA damage checkpoint response, MGMT-mediated DNA 
repair, expression of both drug efflux transporters and anti-apoptotic factors, or 
abnormalities of cell-death pathways (59, 132,138, 141).  
5.3 Constitutively active Notch and PI3K/Akt signaling 
Notch signaling promotes radioresistance of GSC by upregulating PI3K/AKT pathway 
signaling and increasing the expression levels of myeloid cell leukemia-1(MCL1), an anti-
apoptotic member of Bcl-2 family. The knockdown of Notch1 or Notch2 signaling in GSC 
sensitizes GSC to radiation treatment and impairs tumorigenic capacity (142), indicating a 
critical role of Notch/PI3K/AKT signaling in radioresistance of GSC. Moreover, addition of 
GSIs enhances TMZ treatment of human gliomas by inhibiting neurosphere repopulation 
and xenograft recurrence (143), pointing out the essential role of Notch pathway in 
chemoprotection of GSC.  
5.4 Bmi-1-mediated DNA damage response 
Bmi-1 plays important roles in histone H2A ubiquitination and HOX gene silencing, and is a 
potent negative regulator of the Ink4a/Arf locus, which encodes the cell cycle regulators 
and tumor suppressor p16Ink4a and p19Arf genes (144, 145). BMI1 was enriched at the 
chromatin after irradiation and colocalized with ataxia-telangiectasia mutated (ATM) kinase 
and the histone gammaH2AX, an important DNA double strand break (DSB) repair 
pathway (144). A recent study showed that Bmi-1 preferentially copurified with non-
homologous end joining (NHEJ) proteins in CD133+ GSC, suggesting that Bmi-1 confers 
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radioresistance to GSC may through the recruitment of DNA damage response machinery 
(145).  
5.5 Insulin-like growth factor binding protein 2 (IGFBP2) 
IGFBP-2 is a member of a family of six highly conserved IGFBPs that are carriers for the 
IGFs. The heparin-binding domain (HBD) of IGFBP2 has anabolic activity by activating IGF-
I/Akt and ǃ-catenin signaling pathways (146). IGFBP2 is known to be overexpressed in a 
majority of glioblastoma tumors, and its expression is inversely correlated to glioblastoma 
patient survival (40, 147). IGFBP2 enhances tumor invasion by upregulating matrix 
metalloproteinase-2 and CD24 (148, 149). Recent studies indicated that IGFBP2 is 
overexpressed in GSC (42, 150) and autocrine IGFBP2 is required for self-renewal and 
expansion of GSC (150). The knockdown of IGFBP2 expression downregulated the 
expression of stemness-associated gene and reduced AKT activation, and treatment with an 
IGFBP2 neutralizing antibody sensitized GSC to irradiation and multiple anti-neoplastic 
agents (150). As anticipated, recombinant IGFPB2 substantiated AKT signaling-mediated 
GSC viability that could be blocked by treatment with PI3K/Akt inhibitors, suggesting that 
IGFBP2 contributes to anti-apoptotic features of GSC.  
6. Final remarks 
The isolation and characterization of GSC have not only significantly changed the biological 
view of tumors, but has also impacted the design of effective therapies, as radio-
chemoresistant, stem-like, tumorigenic glioblastoma cells may continue seeding the new 
tumor, despite local treatment to the tumor mass. Currently, the GSC hypothesis and model 
are not fully established. However, the accumulated preclinical data generated and 
established from both in-vitro and in-vivo GSC model systems will certainly facilitate the 
exploration of new concepts in tumor biology, tumor relapse and the design of potentially 
more effective treatment protocols that can specifically target GSC with radio-
chemoresistant features. Meanwhile, since CSC share many signaling pathways with normal 
stem cells, exploring differences between normal and tumor stem cells may reveal novel, 
tumor-specific molecular targets for a safe therapy for brain cancer. Moreover, identifying 
the extrinsic cues and effects from their niche on GSC is also crucial as they may provide 
vital signaling to modulate GSC physiology and pathology (151-152). The cure for cancer 
requires eliminating both GSC and non-GSC populations; thus, it is important to design 
preclinical studies and clinical trials which evaluate the synergistic benefits of incorporating 
GSC-targeted therapies into conventional cancer treatments. Based on the molecular 
pathways of gliblastoma and GSC discussed in this chapter, I designed a therapeutic model 
for targeting both fast-growing, hyper-angiogenic glioblastoma tumor cells and slow-
cycling, quiescent, anti-apoptotic GSC; the model theoretically and ideally, can prevent post-
treatment tumor recurrence (Figure 6). 
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Fig. 6. A model of glioblastoma stem cell (GSC)-targeted brain cancer therapy. GSC utilize 
multiple stem cell associated-signaling pathways to achieve a radio-chemoresistant 
phenotype that sustains tumorigenesis. Essential gene pathways as indicated have been 
determined to be required for maintaining stemness properties, tumorigenic capacity and a 
radio-chemoresistant phenotype of GSC. Radiochemoresistance may be accomplished via 
collaboration of constitutive activation of the DNA damage checkpoint response and PI3K-
Akt signaling pathway, high expression of both anti-apoptotic proteins and drug efflux 
transporters, and evasion of both differentiation and irreversible cell cycle arrest (cellular 
quiescence). In order to eradicate a tumor and prevent post-treatment tumor recurrence, a 
therapeutic strategy that target essential gene pathways for maintaining GSC must be 
developed to be fully integrated into radio-chemotherapy and anti-angiogenic therapy in 
order to target both quiescent GSC and fast-growing, angiogenic non-GSC populations. 
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